

EU Grant awarded through Vinnova

SpectraCure has been granted a research and development grant linked to EU's major research and innovation Framework Programme, Horizon 2020. The grant is in the Industrial leadership sub-area, and is a so-called SME instrument in Phase 1, a contribution towards small and medium-sized research companies.

The grant includes SEK 500 000 in Phase 1, and is aimed at a feasibility study for the continued development of the next generation of SpectraCure's technology for photodynamic tumour therapy of recurring prostate cancer. The pre-study is to be conducted within six months. Next, SpectraCure plans to go ahead and apply for a contribution for phase 2 in the same area, where larger grant sums are involved, for, among other things, the support of clinical studies. The Phase 1 grant is paid by Swedish Vinnova, when SpectraCure's application received an evaluation score above the threshold.

"It is very gratifying that our application in the SME instrument has been granted," says CEO Masoud Khayyami. There is great competition and many seeking within the SME instrument and most applications do not reach the required evaluation points. This shows that the reviewers of the project believe that SpectraCure's method has a high scientific level and innovation height.

The feasibility study will be conducted during the autumn of 2017.

For further information, contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.